Login to Your Account



Hutchison-discovered fruquintinib moves into phase III CRC trial

By Cornelia Zou
Staff Writer

Tuesday, December 16, 2014
HONG KONG – The R&D arm of a China-based health care group owned by the multinational conglomerate Hutchison Whampoa Ltd. (HK:13) has moved its leading oncology candidate into phase III.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription